web analytics
17 C
Munich
Tuesday, August 3, 2021

Blue Skies; Enzolytics Inc (OTCMKTS: ENZC) BioClonetics Merger

Enzolytics Inc (OTCMKTS: ENZC) is making a powerful run up the charts in recent days rocketing past all previous highs and entering a blue sky breakout. The dollar volume has been climbing too topping $4 million on Friday alone. The move on ENZC comes as the Company merges with another biotech; BioClonetics; a Company that has created a cell line that produces a fully human monoclonal antibody, the Clone 3 antibody, that binds to and neutralizes the HIV virus. Monoclonal antibodies are big in the fight against coronavirus and Enzolytics has taken the fight to ground zero recently expanding its lab to the campus of Texas A&M University at the Institute for Preclinical Studies. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus.

Enzolytics has quickly attracted a power house team behind it which speaks of big things to come here. They recently appointed Ronald Moss, M.D., to the Medical Advisory Board. Mr. Moss has been an executive with numerous biotech’s over the past 25 years. He has extensive clinical and regulatory management expertise in guiding programs through Phase I, II, and III clinical trials, including IND and NDA experience. The Company’s Chief Science Officer, Mr. Henry Zhabilov has managed several clinical trials utilizing therapeutic proteins. He is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company’s IPF platform.

Enzolytics Inc (OTCMKTS: ENZC) is a Dallas Texas biotech company with a proprietary methodology and expertise for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. From this methodology, the company has created proprietary cell lines that produce fully human monoclonal antibodies that target and neutralize infectious diseases including HIV, influenza, tetanus, diphtheria, and coronavirus.

Enzolytics, Inc.’s flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective.

Enzolytics currently holds a 49% Interest in Immunotech Laboratories BG-Europe. Immunotech BG-Europe has a license for the development and commercialization of Enzolytics Patented ITV-1 Technology. Immunotech BG-Europe, under the branded ImmunH , utilizing the technology has successfully completed Phase III clinical trials at the Specialized Hospital for Active Treatment of Infectious and Parasite Disease in Sofia, Bulgaria, specific for the treatment of HIV/AIDS.ImmunoTech Laboratories BG-Europe has filed for a mass use permit, Phase IV, in Bulgaria. Enzolytics is seeking a Contract Manufacturing Organization (CMO) in the United States to produce the Immunotherapy Treatment to be used as the validation batch in coordination with the Bulgarian regulatory authority and Immunotech BG-Europe.Additionally, ImmunoTech BG-Europe has informed Enzolytics that they will be seeking to register the ImmunH product as a ImmuneModulator, allowing use as an adjunct in additional applications to regulate or normalize the Immune System.

The big story on ENZC is the BioClonetics merger which Microcapdaily first reported on when ENZC was sub $0.003. The newly combined Companies plan to combine BioClonetics Clone 3 recombinant mAbs with Enzolytics’ flagship compound ITV-1; a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has been shown to not be subject to viral resistance and is cost effective. The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates.

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZC

The Company is led by majority shareholder and CEO Charles S. Cotropia, a well-known intellectual property attorney who has litigated over 200 patents in his career and served as lead counsel in several landmark patent disputes litigated in Federal Courts and the US Patent and Trademark Office. Prior to co-founding BioCLonetics, Mr. Cotropia served as a partner and senior counsel at Sidley Austin LLP.  Mr. Cotropia founded BioCLonetics along with his brother Dr. Joseph Cotropia, MD, who pioneered BioCLonetics proprietary method for creating human cell lines that produce human antibodies directed against many infectious diseases. One cell (designated as CLONE 3) has been demonstrated in multiple tests and 5 Independent studies to neutralize the HIV virus in 98% of all known varieties world-wide.

Recently Enzolytics expanded its lab to the campus of Texas A&M University at the Institute for Preclinical Studies. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. Texas A&M University is ground zero for coronavirus research; the US government has reserved a high-tech bio-manufacturing facility at Texas A&M University for mass production of a COVID-19 vaccine as part of a program implemented by President Donald Trump. As the virus is constantly mutating there will always be a need for additional monoclonal antibodies to be used together with those initially discovered. Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified that a success in treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies – meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms.

Charles Cotropia commented recently: “We welcome the recent news from Eli Lilly regarding its production of monoclonal antibodies for treatment of COVID-19 patients. We note that experts agree that for a monoclonal antibody therapy to be effective, a “combination” (or “cocktail”) of such antibodies used in combination will likely be needed. Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified (as recently in his keynote address at the AIDS International Conference) that a success in treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies – meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms. Thus, we recognize that while other pharma companies may produce effective antibodies, there will necessarily be a need for additional monoclonal antibodies to be used in tantum with those initially discovered. Also, and unfortunately, the mutation of viruses, both the HIV and the CoronaVirus, will necessitate the production of numerous effective antibodies as the virus mutates around the therapeutics initially discovered.”

 

For more on ENZC Subscribe Right Now!

Currently making a powerful run up the charts ENZC has surpassed all previous highs and is now on a blue sky breakout. The dollar volume has been climbing too topping $4 million on Friday alone. The move on ENZC comes as the Company merges with another biotech; BioClonetics; a Company that has created a cell line that produces a fully human monoclonal antibody, the Clone 3 antibody, that binds to and neutralizes the HIV virus. Monoclonal antibodies are big in the fight against coronavirus and Enzolytics is making moves recently expanding its lab to the campus of Texas A&M University at the Institute for Preclinical Studies. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the CoronaVirus and collaborate with the biopharma experts on the campus. Enzolytics has quickly attracted a power house team behind it which speaks of big things to come here. They recently appointed Ronald Moss, M.D., to the Medical Advisory Board. Mr. Moss has been an executive with numerous biotech’s over the past 25 years. He has extensive clinical and regulatory management expertise in guiding programs through Phase I, II, and III clinical trials, including IND and NDA experience. The Company’s Chief Science Officer, Mr. Henry Zhabilov has managed several clinical trials utilizing therapeutic proteins. He is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company’s IPF platform. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

More articles

2 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.